An IgA anti-transglutaminase 2 (TGA-IgA) antibody cut-off of approximately 6.1 times the upper limit of normal optimised celiac disease diagnosis in children and adolescents with type 1 diabetes (T1D) ...
San Diego, CA (October 25, 2024) — IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics ...
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...
The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows ...
At the American Society of Nephrology (ASN) Kidney Week meeting, an interim analysis of a phase III trial of sibeprenlimab in immunoglobulin A (IgA) nephropathy showed a nearly 50% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results